Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cue Biopharma, Inc. (CUE)
USD28.49
-2.79 (-8.92%)
US NASDAQ Healthcare Biotechnology
Address
21 Erie Street 2139
Boston, MA, US
Boston, MA, US
CEO
Lucinda Warren
Website
cuebiopharma.com
IPO
2018-01-02
CIK 1645460 ISIN US22978P2056
Description
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
- Cue Biopharma Announces $50.0 Million Private Placement GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD28.49
-2.79 (-8.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
765.3K
Beta
2.46
Float Shares
2.61M
Free Float %
99.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.16% | -29.22% | +26.50% | +163.57% | +33.62% | +151.20% | +8.44% | -81.06% | -94.52% | -93.40% | -93.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
28.49
Low
2.00
-93.0%
Consensus
4.33
-84.8%
Median
4.00
-86.0%
High
7.00
-75.4%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 4 |
4.75
-83.3%
|
Quality scores
Altman Z-Score
-13.35
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+195.8% ★ Q1'26: +1,250.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+61.1% ★ Q1'26: +78.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-99.7% Q1'26: -194.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-96.6% Q1'26: -94.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-759.3% Q1'26: -247.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+68.2% Q1'26: +94.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.18× Q1'26: -0.16× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.14M
est: 788.0K (+45.0%)
|
3.46M
est: 3.28M (+5.4%)
|
3.15M
est: 3.83M (-17.7%)
|
14.94M
est: 7.57M (+97.5%)
|
1.25M
est: 1.20M (+3.9%)
|
5.49M
est: 8.30M (-33.8%)
|
9.29M
est: 9.41M (-1.3%)
|
27.47M
est: 6.50M (+322.6%)
|
12.80M
12.80M – 12.80M
+96.9% YoY
|
1.00M
1.00M – 1.00M
-92.2% YoY
|
1.00M
1.00M – 1.00M
+0.0% YoY
|
1.00M
1.00M – 1.00M
+0.0% YoY
|
| EBITDA |
-37.94M
est: -788.0K (-4,714.3%)
|
-35.96M
est: -3.28M (-995.8%)
|
-43.99M
est: -3.83M (-1,047.7%)
|
-45.44M
est: -7.57M (-500.6%)
|
-50.49M
est: -1.20M (-4,115.5%)
|
-46.05M
est: -8.03M (-473.7%)
|
-37.53M
est: -9.11M (-312.1%)
|
-23.04M
est: -6.29M (-266.3%)
|
-12.39M
-12.39M – -12.39M
-96.9% YoY
|
-967.8K
-967.8K – -967.8K
+92.2% YoY
|
-967.8K
-967.8K – -967.8K
+0.0% YoY
|
-967.8K
-967.8K – -967.8K
+0.0% YoY
|
| EBIT |
-38.70M
est: -788.0K (-4,810.7%)
|
-36.77M
est: -3.28M (-1,020.5%)
|
-45.04M
est: -3.83M (-1,075.3%)
|
-43.67M
est: -7.57M (-477.1%)
|
-52.30M
est: -1.20M (-4,266.3%)
|
-49.49M
est: -8.24M (-500.7%)
|
-39.88M
est: -9.35M (-326.7%)
|
-26.52M
est: -6.46M (-310.8%)
|
-12.71M
-12.71M – -12.71M
-96.9% YoY
|
-993.1K
-993.1K – -993.1K
+92.2% YoY
|
-993.1K
-993.1K – -993.1K
+0.0% YoY
|
-993.1K
-993.1K – -993.1K
+0.0% YoY
|
| Net Income |
-38.98M
est: -85.62M (+54.5%)
|
-36.70M
est: -96.60M (+62.0%)
|
-44.78M
est: -85.41M (+47.6%)
|
-44.16M
est: -86.56M (+49.0%)
|
-53.01M
est: -76.18M (+30.4%)
|
-50.73M
est: -3.07M (-1,552.7%)
|
-40.67M
est: -70.18M (+42.0%)
|
-26.60M
est: -37.89M (+29.8%)
|
-20.97M
-20.97M – -20.97M
+44.7% YoY
|
-29.84M
-29.84M – -29.84M
-42.3% YoY
|
-48.31M
-48.31M – -48.31M
-61.9% YoY
|
-49.26M
-49.26M – -49.26M
-2.0% YoY
|
| SGA |
11.30M
est: 3.69M (+206.3%)
|
12.74M
est: 15.36M (-17.0%)
|
14.65M
est: 17.94M (-18.3%)
|
17.31M
est: 35.41M (-51.1%)
|
16.17M
est: 5.61M (+188.5%)
|
16.68M
est: 32.09M (-48.0%)
|
14.59M
est: 36.41M (-59.9%)
|
16.24M
est: 25.15M (-35.4%)
|
49.52M
49.52M – 49.52M
+96.9% YoY
|
3.87M
3.87M – 3.87M
-92.2% YoY
|
3.87M
3.87M – 3.87M
+0.0% YoY
|
3.87M
3.87M – 3.87M
+0.0% YoY
|
| EPS |
-58.20
est: -1.52 (-3,728.9%)
|
-49.80
est: -1.72 (-2,803.8%)
|
-46.80
est: -1.52 (-2,986.6%)
|
-42.30
est: -1.54 (-2,652.7%)
|
-44.70
est: -1.35 (-3,205.0%)
|
-33.30
est: -0.97 (-3,325.5%)
|
-21.60
est: -22.08 (+2.2%)
|
-8.40
est: -12.00 (+30.0%)
|
-6.64
-6.64 – -6.64
+44.7% YoY
|
-9.45
-9.45 – -9.45
-42.3% YoY
|
-15.30
-15.30 – -15.30
-61.9% YoY
|
-15.60
-15.60 – -15.60
-2.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.70M
OE per share TTM
-0.98
Owner's Yield
-3.34%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
84.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
39
Total invested
4.05M
Insider transactions (90d)
2
Beneficial owners (>5%)
17
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Daniel Mack | 2.54M | 8.00% | — | 2.54M | — | — | HC | USA | 2022-02-14 | ↗ |
| 2 | Nantahala Capital Management, LLC | 2.54M | 8.00% | — | 2.54M | — | — | IA | MA | 2022-02-14 | ↗ |
| 3 | Wilmot B. Harkey | 2.54M | 8.00% | — | 2.54M | — | — | HC | USA | 2022-02-14 | ↗ |
| 4 | David Greenspan | 2.40M | 5.60% | — | 2.40M | — | — | IN | United States | 2023-02-14 | ↗ |
| 5 | Jades GP, LLC | 2.40M | 5.60% | — | — | 2.40M | — | OO | Cayman Islands | 2022-11-18 | ↗ |
| 6 | Slate Path Capital LP | 2.40M | 5.60% | — | 2.40M | — | — | IA, PN | Delaware | 2023-02-14 | ↗ |
| 7 | Slate Path Master Fund LP | 2.40M | 5.60% | — | — | 2.40M | — | PN | Cayman Islands | 2022-11-18 | ↗ |
| 8 | (1) BlackRock, Inc. | 2.25M | 4.98% | 2.24M | — | 2.25M | — | HC | Delaware | 2024-02-07 | ↗ |
| 9 | STATE STREET CORPORATION | 1.66M | 5.23% | — | 1.60M | — | 1.66M | HC | — | 2022-02-10 | ↗ |
| 10 | Peter A. Appel | 1.52M | 7.60% | 1.52M | — | 1.52M | — | IN | United States | 2018-02-13 | ↗ |
| 11 | Christopher A. Marlett | 1.46M | 6.17% | 1.45M | 9.0K | 1.45M | 9.0K | IN | United States | 2019-12-18 | ↗ |
| 12 | Mark E. Strome | 1.15M | 5.70% | — | — | — | — | IN | United State of America | 2018-01-09 | ↗ |
| 13 | Avoro Capital Advisors LLC | 452.5K | 1.50% | 452.5K | — | 452.5K | — | IA, OO | Delaware | 2021-02-12 | ↗ |
| 14 | Behzad Aghazadeh | 452.5K | 1.50% | 452.5K | — | 452.5K | — | IN | United States | 2021-02-12 | ↗ |
| 15 | Corriente Advisors, LLC | — | 0.00% | — | — | — | — | OO | Citizenship or place of organization | 2022-02-14 | ↗ |
| 16 | Corriente Master Fund II, LP | — | 0.00% | — | — | — | — | PN | Citizenship or place of organization | 2022-02-14 | ↗ |
| 17 | Mark L. Hart III | — | 0.00% | — | — | — | — | IN | Citizenship or place of organization | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
39
-9 vs prev Q
New positions
10
Closed positions
19
Increased
11
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLEICHROEDER LP | 6.82M +— (+0.0%) | 2.08M -2.8M (-57.5%) | 6.76% -0.383 pp | 0.37% -0.589 pp | USD1.77 -82.5% | 25 qtrs — |
| 2 | CATALYTIC WEALTH RIA, LLC | 4.63M +1.2M (+35.0%) | 1.41M -1.1M (-42.6%) | 4.59% +0.997 pp | 0.05% -0.029 pp | USD0.59 -47.5% | 3 qtrs — |
| 3 | VANGUARD GROUP INC | 3.01M -25.3K (-0.8%) | 919.3K -1.3M (-57.9%) | 2.99% -0.196 pp | 0.00% +0.000 pp | USD7.05 -95.6% | 32 qtrs — |
| 4 | LION POINT CAPITAL, LP | 2.20M +2.2M (+100.0%) | 672.8K +672.8K (+100.0%) | 2.18% +2.184 pp | 3.48% +3.482 pp | USD0.31 +0.0% | 1 qtrs NEW |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 803.3K +2.5K (+0.3%) | 245.4K -330.2K (-57.4%) | 0.80% -0.043 pp | 0.00% +0.000 pp | USD4.61 -93.3% | 32 qtrs — |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | 704.3K +93.3K (+15.3%) | 215.1K -224.0K (-51.0%) | 0.70% +0.058 pp | 0.00% -0.003 pp | USD0.66 -53.0% | 2 qtrs — |
| 7 | ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC | 478.5K +— (+0.0%) | 146.1K -197.8K (-57.5%) | 0.47% -0.027 pp | 0.00% -0.007 pp | USD15.05 -97.9% | 22 qtrs — |
| 8 | BLACKROCK, INC. | 449.2K +— (+0.0%) | 137.2K -185.6K (-57.5%) | 0.45% -0.025 pp | 0.00% +0.000 pp | USD0.79 -60.8% | 6 qtrs — |
| 9 | TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC | 440.7K +407.6K (+1,231.2%) | 134.6K +110.8K (+465.7%) | 0.44% +0.402 pp | 0.01% +0.006 pp | USD0.36 -13.9% | 5 qtrs — |
| 10 | ANGELES WEALTH MANAGEMENT, LLC | 310.0K +190.0K (+158.3%) | 94.7K +8.4K (+9.8%) | 0.31% +0.182 pp | 0.01% 0.000 pp | USD0.45 -31.1% | 3 qtrs — |
| 11 | ADVISORY RESEARCH INC | 257.2K +— (+0.0%) | 78.6K -106.3K (-57.5%) | 0.26% -0.015 pp | 0.01% -0.014 pp | USD12.20 -97.5% | 20 qtrs — |
| 12 | STIFEL FINANCIAL CORP | 246.6K +50.0K (+25.4%) | 75.3K -66.0K (-46.7%) | 0.24% +0.039 pp | 0.00% 0.000 pp | USD4.31 -92.8% | 27 qtrs — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 238.4K +11.3K (+5.0%) | 72.8K -90.4K (-55.4%) | 0.24% -0.002 pp | 0.00% 0.000 pp | USD0.71 -56.3% | 4 qtrs — |
| 14 | BANK OF AMERICA CORP /DE/ | 207.6K -117.0K (-36.0%) | 63.3K -169.7K (-72.8%) | 0.21% -0.134 pp | 0.00% +0.000 pp | USD2.84 -89.1% | 32 qtrs — |
| 15 | STATE STREET CORP | 179.4K -10.4K (-5.5%) | 54.8K -81.6K (-59.8%) | 0.18% -0.021 pp | 0.00% +0.000 pp | USD5.47 -94.3% | 32 qtrs — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 168.8K +2.4K (+1.4%) | 51.6K -68.1K (-56.9%) | 0.17% -0.007 pp | 0.00% +0.000 pp | USD0.68 -54.4% | 23 qtrs — |
| 17 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 85.9K +— (+0.0%) | 32.7K -30.8K (-48.5%) | 0.09% -0.005 pp | 0.00% -0.001 pp | USD0.91 -65.9% | 4 qtrs — |
| 18 | NORTHERN TRUST CORP | 101.0K +— (+0.0%) | 30.8K -41.7K (-57.5%) | 0.10% -0.006 pp | 0.00% +0.000 pp | USD3.98 -92.2% | 32 qtrs — |
| 19 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 79.5K +— (+0.0%) | 24.3K -32.9K (-57.5%) | 0.08% -0.005 pp | 0.00% +0.000 pp | USD0.72 -56.9% | 11 qtrs — |
| 20 | JANE STREET GROUP, LLC | 69.8K +69.8K (+100.0%) | 21.3K +21.3K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.000 pp | USD0.31 +0.0% | 1 qtrs NEW |
| 21 | UBS GROUP AG | 46.8K -152.3K (-76.5%) | 14.3K -128.9K (-90.0%) | 0.05% -0.162 pp | 0.00% +0.000 pp | USD1.41 -78.0% | 32 qtrs — |
| 22 | LPL FINANCIAL LLC | 46.4K +— (+0.0%) | 14.2K -19.2K (-57.5%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD1.24 -75.0% | 14 qtrs — |
| 23 | SIGMA PLANNING CORP | 41.1K -12.3K (-23.0%) | 12.5K -25.8K (-67.3%) | 0.04% -0.015 pp | 0.00% -0.001 pp | USD2.41 -87.1% | 28 qtrs — |
| 24 | NEWEDGE ADVISORS, LLC | 20.0K +— (+0.0%) | 6.1K -8.3K (-57.5%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD0.73 -57.5% | 7 qtrs — |
| 25 | HRT FINANCIAL LP | 20.9K +20.9K (+100.0%) | 6.0K +6.0K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD0.31 +0.0% | 7 qtrs — |
| 26 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 20.0K +— (+0.0%) | 6.0K -8.0K (-57.1%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.52 -91.2% | 11 qtrs — |
| 27 | PREVAIL INNOVATIVE WEALTH ADVISORS, LLC | 19.0K +— (+0.0%) | 5.8K -7.8K (-57.5%) | 0.02% -0.001 pp | 0.00% -0.002 pp | USD0.68 -54.4% | 3 qtrs — |
| 28 | MORGAN STANLEY | 18.6K -8.9K (-32.4%) | 5.7K -14.1K (-71.3%) | 0.02% -0.010 pp | 0.00% +0.000 pp | USD5.40 -94.3% | 32 qtrs — |
| 29 | GOLDMAN SACHS GROUP INC | 14.4K -19.0 (-0.1%) | 4.4K -6.0K (-57.6%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.51 -79.5% | 24 qtrs — |
| 30 | SEACREST WEALTH MANAGEMENT, LLC | 10.0K +— (+0.0%) | 3.9K -4.7K (-54.9%) | 0.01% -0.001 pp | 0.00% -0.001 pp | USD12.51 -97.5% | 21 qtrs — |
| 31 | HIGHTOWER ADVISORS, LLC | 10.9K +10.9K (+100.0%) | 3.3K +3.3K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.000 pp | USD0.31 +0.0% | 1 qtrs NEW |
| 32 | BARCLAYS PLC | 6.0K +— (+0.0%) | 1.8K -2.7K (-59.7%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD3.79 -91.8% | 32 qtrs — |
| 33 | GLEASON GROUP, INC. | 6.0K +— (+0.0%) | 1.8K -2.5K (-57.5%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD3.65 -91.5% | 11 qtrs — |
| 34 | NEW MILLENNIUM GROUP LLC | 5.8K +5.8K (+100.0%) | 1.8K +1.8K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD0.31 +0.0% | 1 qtrs NEW |
| 35 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 3.0K +— (+0.0%) | 916.00 -1.2K (-57.5%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD4.73 -93.4% | 22 qtrs — |
| 36 | WELLS FARGO & COMPANY/MN | 2.6K -17.0K (-86.9%) | 783.00 -13.3K (-94.4%) | 0.00% -0.018 pp | 0.00% +0.000 pp | USD3.82 -91.9% | 32 qtrs — |
| 37 | SIMPLEX TRADING, LLC | 2.6K -2.3K (-47.1%) | 780.00 -2.2K (-74.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD0.72 -56.9% | 20 qtrs — |
| 38 | GOLDEN STATE WEALTH MANAGEMENT, LLC | 2.0K +— (+0.0%) | 611.00 -826.0 (-57.5%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD1.09 -71.6% | 5 qtrs — |
| 39 | TIDEMARK, LLC | 1.5K +— (+0.0%) | 458.00 -620.0 (-57.5%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD0.91 -65.9% | 4 qtrs — |
| 40 | PHYSICIAN WEALTH ADVISORS, INC. | 1.0K +— (+0.0%) | 308.00 -416.0 (-57.5%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD1.09 -71.6% | 5 qtrs — |
| 41 | ADVISOR GROUP HOLDINGS, INC. | 680.00 +— (+0.0%) | 209.00 -303.0 (-59.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.09 -85.2% | 24 qtrs — |
| 42 | BNP PARIBAS ARBITRAGE, SNC | 415.00 -275.0 (-39.9%) | 127.00 -369.0 (-74.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.72 -88.6% | 32 qtrs — |
| 43 | JONES FINANCIAL COMPANIES LLLP | 400.00 +400.0 (+100.0%) | 122.00 +122.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.31 +0.0% | 1 qtrs NEW |
| 44 | MAI CAPITAL MANAGEMENT | 350.00 +— (+0.0%) | 107.00 -145.0 (-57.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.09 -71.6% | 5 qtrs — |
| 45 | — | 324.00 +324.0 (+100.0%) | 99.00 +99.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.30 +3.3% | 1 qtrs NEW |
| 46 | ARMSTRONG ADVISORY GROUP, INC | 120.00 +— (+0.0%) | 37.00 -50.0 (-57.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.85 -89.1% | 13 qtrs — |
| 47 | IFP ADVISORS, INC | 100.00 +— (+0.0%) | 31.00 -41.0 (-56.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.64 -88.3% | 9 qtrs — |
| 48 | JPMORGAN CHASE & CO | 4.00 -900.0 (-99.6%) | 1.00 -649.0 (-99.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.00 -69.0% | 11 qtrs — |
| 49 | TWO SIGMA SECURITIES, LLC | — -39.5K (-100.0%) | — -28.4K (-100.0%) | 0.00% -0.041 pp | 0.00% -0.004 pp | USD— | 4 qtrs SOLD |
| 50 | VIRTU FINANCIAL LLC | — -15.1K (-100.0%) | — -11.0K (-100.0%) | 0.00% -0.016 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 51 | ADVISORY SERVICES NETWORK, LLC | — -200.0 (-100.0%) | — -144.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 52 | XTX TOPCO LTD | — -14.7K (-100.0%) | — -10.6K (-100.0%) | 0.00% -0.015 pp | 0.00% -0.001 pp | USD— | 6 qtrs SOLD |
| 53 | CITIGROUP INC | — -132.0 (-100.0%) | — -95.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 54 | NAVALIGN, LLC | — -25.0K (-100.0%) | — -18.0K (-100.0%) | 0.00% -0.026 pp | 0.00% -0.005 pp | USD— | 9 qtrs SOLD |
| 55 | MATHER GROUP, LLC. | — -1.0K (-100.0%) | — -719.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 56 | SQUAREPOINT OPS LLC | — -85.8K (-100.0%) | — -61.7K (-100.0%) | 0.00% -0.090 pp | 0.00% 0.000 pp | USD— | 12 qtrs SOLD |
| 57 | SUNBELT SECURITIES, INC. | — -237.0 (-100.0%) | — -170.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 12 qtrs SOLD |
| 58 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 59 | TOWER RESEARCH CAPITAL LLC (TRC) | — -10.1K (-100.0%) | — -7.3K (-100.0%) | 0.00% -0.011 pp | 0.00% 0.000 pp | USD— | 11 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.03% | 409.3K | 0.60% |
| 2 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 64.4K | 0.25% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 792.0K | 0.05% |
| 4 | Dimensional - US Small Cap ETF DFAS | 0.00% | 66.3K | 0.26% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 4.3K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 878.83 | 0.17% |
| 7 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 11.9K | 0.17% |
| 8 | Vanguard Total Stock Market ETF VTI | 0.00% | 2.03M | 0.03% |
| 9 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 3.9K | 0.43% |
| 10 | Avantis Total Equity Markets ETF 1 AVTM | 0.00% | 367.96 | 0.23% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
550.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+550,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-03 | Lin Shao-Lee | Director / Officer | A-Award | A | Stock Option (right to buy) | 655,074 | 30.42 | 19.93M | 655,074 | D | ↗ |
| 2026-04-30 | Lin Shao-Lee | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-04-09 | Warren Lucinda | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.29 | 72.5K | 250,000 | D | ↗ |
| 2026-04-09 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.29 | 58.0K | 200,000 | D | ↗ |
| 2026-04-09 | Baker Daniel G. | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.29 | 29.0K | 100,000 | D | ↗ |
| 2026-01-02 | Verheyen Patrick | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 0.34 | 8.3K | 24,400 | D | ↗ |
| 2026-01-02 | Sarraf Pasha | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 0.34 | 8.3K | 24,400 | D | ↗ |
| 2026-01-02 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 0.34 | 8.3K | 24,400 | D | ↗ |
| 2026-01-02 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 0.34 | 8.3K | 24,400 | D | ↗ |
| 2026-01-02 | Garzone Pamela | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 0.34 | 8.3K | 24,400 | D | ↗ |
| 2026-01-02 | Broadfoot Jill Marie | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 0.34 | 8.3K | 24,400 | D | ↗ |
| 2025-12-30 | Sarraf Pasha | Director | P-Purchase | A | Common Stock | 77,417 | 0.30 | 23.3K | 323,857 | D | ↗ |
| 2025-12-03 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 0.70 | 49.0K | 70,000 | D | ↗ |
| 2025-09-29 | Warren Lucinda | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 0.72 | 90.0K | 125,000 | D | ↗ |
| 2025-09-29 | Baker Daniel G. | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.72 | 36.0K | 50,000 | D | ↗ |
| 2025-09-29 | Azam Usman | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,875,000 | 0.72 | 1.35M | 1,875,000 | D | ↗ |
| 2025-09-26 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 0.70 | 21.0K | 30,000 | D | ↗ |
| 2025-06-04 | Broadfoot Jill Marie | Director | A-Award | A | Stock Option (right to buy) | 48,800 | 0.62 | 30.3K | 48,800 | D | ↗ |
| 2025-03-21 | Warren Lucinda | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.99 | 247.5K | 250,000 | D | ↗ |
| 2025-03-21 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.99 | 198.0K | 200,000 | D | ↗ |
| 2025-03-21 | PASSERI DANIEL R | Director / Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 0.99 | 445.5K | 450,000 | D | ↗ |
| 2025-03-21 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.99 | 198.0K | 200,000 | D | ↗ |
| 2025-03-21 | Levisetti Matteo | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.99 | 247.5K | 250,000 | D | ↗ |
| 2025-03-21 | Baker Daniel G. | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.99 | 99.0K | 100,000 | D | ↗ |
| 2025-03-10 | Sarraf Pasha | Director | A-Award | A | Stock Option (right to buy) | 48,800 | 1.03 | 50.3K | 48,800 | D | ↗ |
| 2025-01-02 | Verheyen Patrick | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 1.09 | 26.6K | 24,400 | D | ↗ |
| 2025-01-02 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 1.09 | 26.6K | 24,400 | D | ↗ |
| 2025-01-02 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 1.09 | 26.6K | 24,400 | D | ↗ |
| 2025-01-02 | Garzone Pamela | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 1.09 | 26.6K | 24,400 | D | ↗ |
| 2025-01-02 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 1.09 | 26.6K | 24,400 | D | ↗ |
| 2024-12-16 | PASSERI DANIEL R | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 1.03 | 30.9K | 164,578 | D | ↗ |
| 2024-11-25 | Baker Daniel G. | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 1.06 | 212.0K | 200,000 | D | ↗ |
| 2024-09-03 | Warren Lucinda | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-05 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 1.65 | 247.5K | 150,000 | — | ↗ |
| 2024-06-05 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 1.65 | 99.0K | 60,000 | — | ↗ |
| 2024-06-05 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 1.65 | 99.0K | 60,000 | — | ↗ |
| 2024-06-05 | Levisetti Matteo | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 1.65 | 206.3K | 125,000 | — | ↗ |
| 2024-06-05 | Fox Michael J | Director | A-Award | A | Stock Option (right to buy) | 48,800 | 1.65 | 80.5K | 48,800 | — | ↗ |
| 2024-03-06 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 1.94 | 582.0K | 300,000 | — | ↗ |
| 2024-03-06 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 1.94 | 339.5K | 175,000 | — | ↗ |
| 2024-03-06 | PASSERI DANIEL R | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 1.94 | 776.0K | 400,000 | — | ↗ |
| 2024-03-06 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 1.94 | 485.0K | 250,000 | — | ↗ |
| 2024-03-06 | Levisetti Matteo | Officer | A-Award | A | Stock Option (right to buy) | 260,000 | 1.94 | 504.4K | 260,000 | — | ↗ |
| 2024-02-20 | Levisetti Matteo | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 3.36 | 84.0K | 25,000 | — | ↗ |
| 2024-01-02 | Verheyen Patrick | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 2.78 | 67.8K | 24,400 | — | ↗ |
| 2024-01-02 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 2.78 | 67.8K | 24,400 | — | ↗ |
| 2024-01-02 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 2.78 | 67.8K | 24,400 | — | ↗ |
| 2024-01-02 | Garzone Pamela | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 2.78 | 67.8K | 24,400 | — | ↗ |
| 2024-01-02 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (right to buy) | 24,400 | 2.78 | 67.8K | 24,400 | — | ↗ |
| 2023-08-25 | Suri Anish | Officer | P-Purchase | A | Common Stock | 4,000 | 2.76 | 11.0K | 135,638 | — | ↗ |
| 2023-08-14 | PASSERI DANIEL R | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 2.86 | 8.6K | 134,578 | — | ↗ |
| 2023-07-21 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 124,125 | 4.20 | 521.3K | 124,125 | — | ↗ |
| 2023-07-21 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 4.20 | 315.0K | 75,000 | — | ↗ |
| 2023-07-21 | PASSERI DANIEL R | Director / Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 4.20 | 1.89M | 450,000 | — | ↗ |
| 2023-07-21 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 113,000 | 4.20 | 474.6K | 113,000 | — | ↗ |
| 2023-07-21 | Levisetti Matteo | Officer | A-Award | A | Stock Option (right to buy) | 82,500 | 4.20 | 346.5K | 82,500 | — | ↗ |
| 2023-04-19 | Garzone Pamela | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-11 | Verheyen Patrick | Director | — | D | Common Stock | 0 | 0.00 | — | 8,174 | — | ↗ |
| 2023-03-23 | Kiener Peter A | Director | M-Exempt | A | Common Stock | 9,682 | 2.86 | 27.7K | 9,682 | — | ↗ |
| 2023-02-16 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 125,500 | 3.21 | 402.9K | 125,500 | — | ↗ |
| 2023-02-16 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 3.21 | 321.0K | 100,000 | — | ↗ |
| 2023-02-16 | PASSERI DANIEL R | Director / Officer | A-Award | A | Stock Option (right to buy) | 324,000 | 3.21 | 1.04M | 324,000 | — | ↗ |
| 2023-02-16 | NASSHORN PATRICIA | Officer | A-Award | A | Stock Option (right to buy) | 97,900 | 3.21 | 314.3K | 97,900 | — | ↗ |
| 2023-02-16 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 124,000 | 3.21 | 398.0K | 124,000 | — | ↗ |
| 2023-01-17 | Levisetti Matteo | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 0.00 | — | 110,000 | — | ↗ |
| 2023-01-03 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2023-01-03 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2023-01-03 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2023-01-03 | Fletcher Aaron G.L. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2023-01-03 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-08-21 | Millar Kerri-Ann | Officer | F-InKind | D | Common Stock | 2,828 | 3.05 | 8.6K | 14,311 | — | ↗ |
| 2022-06-14 | Gray Cameron | Director | X-InTheMoney | A | Common Stock | 61,111 | 2.70 | 165.0K | 738,611 | — | ↗ |
| 2022-05-27 | Morich Frank | Director | P-Purchase | A | Common Stock | 28,000 | 3.75 | 105.0K | 28,000 | — | ↗ |
| 2022-05-23 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 55,000 | 3.34 | 183.7K | 940,000 | — | ↗ |
| 2022-03-31 | Suri Anish | Officer | F-InKind | D | Common Stock | 7,068 | 4.88 | 34.5K | 103,638 | — | ↗ |
| 2022-03-31 | PASSERI DANIEL R | Officer | F-InKind | D | Common Stock | 32,122 | 4.88 | 156.8K | 141,578 | — | ↗ |
| 2022-03-31 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 735,000 | 4.76 | 3.50M | 735,000 | — | ↗ |
| 2022-03-25 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 21,333 | 5.01 | 106.9K | 21,333 | — | ↗ |
| 2022-03-25 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 16,667 | 5.01 | 83.5K | 16,667 | — | ↗ |
| 2022-03-25 | Pienta Kenneth | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 5.01 | 200.4K | 40,000 | — | ↗ |
| 2022-03-25 | PASSERI DANIEL R | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-03-25 | NASSHORN PATRICIA | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-03-25 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 5.01 | 50.1K | 10,000 | — | ↗ |
| 2022-02-09 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 82,000 | 6.91 | 566.6K | 82,000 | — | ↗ |
| 2022-02-09 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 6.91 | 414.6K | 60,000 | — | ↗ |
| 2022-02-09 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 6.91 | 587.4K | 85,000 | — | ↗ |
| 2022-01-03 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.28 | 122.8K | 10,000 | — | ↗ |
| 2022-01-03 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.28 | 122.8K | 10,000 | — | ↗ |
| 2022-01-03 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.28 | 122.8K | 10,000 | — | ↗ |
| 2022-01-03 | Gray Cameron | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.28 | 122.8K | 10,000 | — | ↗ |
| 2022-01-03 | Fletcher Aaron G.L. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.28 | 122.8K | 10,000 | — | ↗ |
| 2022-01-03 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.28 | 122.8K | 10,000 | — | ↗ |
| 2021-12-20 | Pienta Kenneth | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 11.45 | 916.0K | 80,000 | — | ↗ |
| 2021-12-15 | NASSHORN PATRICIA | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 11.24 | 1.12M | 100,000 | — | ↗ |
| 2021-11-16 | Kiener Peter A | Director | M-Exempt | D | Stock Option (right to buy) | 1,361 | 2.86 | 3.9K | 105,744 | — | ↗ |
| 2021-11-15 | Suri Anish | Officer | S-Sale | D | Common Stock | 8,000 | 18.05 | 144.4K | 94,038 | — | ↗ |
| 2021-11-15 | Kiener Peter A | Director | S-Sale | D | Common Stock | 18,815 | 17.92 | 337.2K | 0 | — | ↗ |
| 2021-11-11 | Suri Anish | Officer | M-Exempt | A | Common Stock | 20,000 | 6.42 | 128.4K | 114,038 | — | ↗ |
| 2021-10-06 | Suri Anish | Officer | F-InKind | D | Common Stock | 14,134 | 12.97 | 183.3K | 94,038 | — | ↗ |
| 2021-10-03 | Suri Anish | Officer | M-Exempt | A | Common Stock | 33,334 | 0.00 | — | 108,172 | — | ↗ |
| 2021-10-01 | Millar Kerri-Ann | Officer | S-Sale | D | Common Stock | 1,251 | 14.21 | 17.8K | 10,472 | — | ↗ |
| 2021-09-30 | PASSERI DANIEL R | Director / Officer | M-Exempt | D | Restricted Stock Units | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2021-09-24 | PASSERI DANIEL R | Director / Officer | P-Purchase | A | Common Stock | 3,400 | 14.72 | 50.1K | 55,377 | — | ↗ |
| 2021-09-23 | Suri Anish | Officer | M-Exempt | A | Common Stock | 20,000 | 6.42 | 128.4K | 94,838 | — | ↗ |
| 2021-08-23 | Millar Kerri-Ann | Officer | F-InKind | D | Common Stock | 1,961 | 0.00 | — | 10,472 | — | ↗ |
| 2021-03-16 | Pienta Kenneth | Officer | M-Exempt | D | Stock Option (right to buy) | 439 | 5.00 | 2.2K | 133,567 | — | ↗ |
| 2021-03-15 | Pienta Kenneth | Officer | S-Sale | D | Common Stock | 13,000 | 15.10 | 196.3K | 2,000 | — | ↗ |
| 2021-02-17 | Pienta Kenneth | Officer | M-Exempt | A | Common Stock | 2,994 | 5.00 | 15.0K | 6,274 | — | ↗ |
| 2021-02-16 | Pienta Kenneth | Officer | M-Exempt | A | Common Stock | 16,000 | 2.86 | 45.8K | 18,000 | — | ↗ |
| 2021-02-10 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 15.55 | 1.17M | 75,000 | — | ↗ |
| 2021-02-10 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 15.55 | 777.5K | 50,000 | — | ↗ |
| 2021-02-10 | Pienta Kenneth | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 15.55 | 777.5K | 50,000 | — | ↗ |
| 2021-02-10 | PASSERI DANIEL R | Director / Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 15.55 | 1.32M | 85,000 | — | ↗ |
| 2021-02-10 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 15.55 | 1.09M | 70,000 | — | ↗ |
| 2021-01-20 | Pienta Kenneth | Officer | P-Purchase | A | Common Stock | 2,720 | 15.07 | 41.0K | 4,720 | — | ↗ |
| 2021-01-04 | Simon Barry J. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.36 | 123.6K | 10,000 | — | ↗ |
| 2021-01-04 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.36 | 123.6K | 10,000 | — | ↗ |
| 2021-01-04 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.36 | 123.6K | 10,000 | — | ↗ |
| 2021-01-04 | HOWSON TAMAR D | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.36 | 123.6K | 10,000 | — | ↗ |
| 2021-01-04 | Gray Cameron | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.36 | 123.6K | 10,000 | — | ↗ |
| 2021-01-04 | Fletcher Aaron G.L. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.36 | 123.6K | 10,000 | — | ↗ |
| 2021-01-04 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.36 | 123.6K | 10,000 | — | ↗ |
| 2020-12-31 | Gray Cameron | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-24 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 6,548 | 12.64 | 82.8K | 165,000 | — | ↗ |
| 2020-10-05 | Suri Anish | Officer | F-InKind | D | Common Stock | 9,800 | 16.30 | 159.7K | 58,091 | — | ↗ |
| 2020-10-03 | Suri Anish | Officer | M-Exempt | A | Common Stock | 33,333 | 0.00 | — | 67,891 | — | ↗ |
| 2020-09-30 | Gray Cameron | Director | P-Purchase | A | Common Stock | 5,000 | 15.30 | 76.5K | 677,500 | — | ↗ |
| 2020-09-29 | Gray Cameron | Director | P-Purchase | A | Common Stock | 5,000 | 15.00 | 75.0K | 672,500 | — | ↗ |
| 2020-09-17 | HOWSON TAMAR D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-24 | Millar Kerri-Ann | Officer | F-InKind | D | Common Stock | 1,900 | 0.00 | — | 5,766 | — | ↗ |
| 2020-08-21 | Millar Kerri-Ann | Officer | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-08-05 | Suri Anish | Officer | M-Exempt | D | Stock Option (right to buy) | 800 | 6.42 | 5.1K | 145,000 | — | ↗ |
| 2020-08-05 | Sandercock Colin | Officer | M-Exempt | D | Stock Option (right to buy) | 13,274 | 7.50 | 99.6K | 130,100 | — | ↗ |
| 2020-08-04 | Suri Anish | Officer | M-Exempt | A | Common Stock | 400 | 6.42 | 2.6K | 34,958 | — | ↗ |
| 2020-08-04 | Sandercock Colin | Officer | M-Exempt | A | Common Stock | 201 | 7.50 | 1.5K | 17,326 | — | ↗ |
| 2020-08-03 | Suri Anish | Officer | M-Exempt | D | Stock Option (right to buy) | 2,000 | 8.26 | 16.5K | 18,000 | — | ↗ |
| 2020-08-03 | Sandercock Colin | Officer | S-Sale | D | Common Stock | 6,425 | 20.00 | 128.5K | 17,125 | — | ↗ |
| 2020-06-24 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 4,547 | 24.64 | 112.0K | 155,499 | — | ↗ |
| 2020-05-11 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 1,200 | 27.56 | 33.1K | 1,200 | — | ↗ |
| 2020-03-31 | Suri Anish | Officer | A-Award | A | Restricted Stock Units | 50,000 | 0.00 | — | 116,667 | — | ↗ |
| 2020-03-24 | Pienta Kenneth | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 14.00 | 1.40M | 100,000 | — | ↗ |
| 2020-02-05 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 16.26 | 1.06M | 65,000 | — | ↗ |
| 2020-02-05 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 16.26 | 325.2K | 20,000 | — | ↗ |
| 2020-02-05 | PASSERI DANIEL R | Director / Officer | A-Award | A | Restricted Stock Units | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2020-02-05 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 16.26 | 487.8K | 30,000 | — | ↗ |
| 2020-01-02 | Simon Barry J. | Director | A-Award | A | Stock Option (right to buy) | 9,600 | 16.31 | 156.6K | 9,600 | — | ↗ |
| 2020-01-02 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 16.31 | 130.5K | 8,000 | — | ↗ |
| 2020-01-02 | MCKNIGHT STEVEN L | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 16.31 | 130.5K | 8,000 | — | ↗ |
| 2020-01-02 | MARLETT CHRISTOPHER A | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 16.31 | 130.5K | 8,000 | — | ↗ |
| 2020-01-02 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 16.31 | 130.5K | 8,000 | — | ↗ |
| 2020-01-02 | Gray Cameron | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 16.31 | 130.5K | 8,000 | — | ↗ |
| 2020-01-02 | Fletcher Aaron G.L. | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 16.31 | 130.5K | 8,000 | — | ↗ |
| 2020-01-02 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 16.31 | 130.5K | 8,000 | — | ↗ |
| 2019-12-31 | MARLETT CHRISTOPHER A | Director | S-Sale | D | Common Stock | 9,000 | 15.71 | 141.4K | 0 | — | ↗ |
| 2019-12-27 | MARLETT CHRISTOPHER A | Director | S-Sale | D | Common Stock | 9,000 | 17.24 | 155.2K | 775,203 | — | ↗ |
| 2019-12-26 | MARLETT CHRISTOPHER A | Director | S-Sale | D | Common Stock | 19,647 | 17.53 | 344.4K | 784,203 | — | ↗ |
| 2019-12-23 | MARLETT CHRISTOPHER A | Director | S-Sale | D | Common Stock | 17,000 | 16.82 | 285.9K | 803,850 | — | ↗ |
| 2019-12-19 | MARLETT CHRISTOPHER A | Director | S-Sale | D | Common Stock | 4,000 | 17.00 | 68.0K | 820,850 | — | ↗ |
| 2019-12-17 | MARLETT CHRISTOPHER A | Director | S-Sale | D | Common Stock | 20,732 | 15.73 | 326.1K | 824,850 | — | ↗ |
| 2019-12-12 | MARLETT CHRISTOPHER A | Director | J-Other | A | Common Stock | 755,980 | 0.00 | — | 845,582 | — | ↗ |
| 2019-11-01 | Suri Anish | Officer | M-Exempt | D | Restricted Stock Units | 33,333 | 0.00 | — | 66,667 | — | ↗ |
| 2019-10-03 | Suri Anish | Officer | A-Award | A | Restricted Stock Units | 100,000 | 0.00 | — | 0 | — | ↗ |
| 2019-10-03 | Fletcher Aaron G.L. | Director | — | I | Common Stock | 0 | 0.00 | — | 8,867 | — | ↗ |
| 2019-06-21 | PASSERI DANIEL R | Director / Officer | P-Purchase | A | Common Stock | 1,377 | 7.26 | 10.0K | 51,977 | — | ↗ |
| 2019-06-10 | Sandercock Colin | Officer | P-Purchase | A | Common Stock | 15,025 | 7.90 | 118.7K | 17,125 | — | ↗ |
| 2019-06-07 | Sandercock Colin | Officer | P-Purchase | A | Common Stock | 100 | 7.35 | 735.00 | 2,100 | — | ↗ |
| 2019-06-06 | Sandercock Colin | Officer | P-Purchase | A | Common Stock | 2,000 | 7.10 | 14.2K | 2,000 | — | ↗ |
| 2019-06-06 | PASSERI DANIEL R | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 6.90 | 20.7K | 50,600 | — | ↗ |
| 2019-03-06 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 11.54 | 1.15M | 100,000 | — | ↗ |
| 2019-03-06 | Sandercock Colin | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 6.42 | 321.0K | 50,000 | — | ↗ |
| 2019-03-06 | PASSERI DANIEL R | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 11.54 | 1.15M | 100,000 | — | ↗ |
| 2019-03-06 | Millar Kerri-Ann | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 6.42 | 192.6K | 30,000 | — | ↗ |
| 2019-03-06 | Mancilla Bethany | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 6.42 | 417.3K | 65,000 | — | ↗ |
| 2019-01-02 | Simon Barry J. | Director | A-Award | A | Stock Option (right to buy) | 9,600 | 5.16 | 49.5K | 9,600 | — | ↗ |
| 2019-01-02 | Morich Frank | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.16 | 41.3K | 8,000 | — | ↗ |
| 2019-01-02 | MCKNIGHT STEVEN L | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.16 | 41.3K | 8,000 | — | ↗ |
| 2019-01-02 | MARLETT CHRISTOPHER A | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.16 | 41.3K | 8,000 | — | ↗ |
| 2019-01-02 | Kiener Peter A | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.16 | 41.3K | 8,000 | — | ↗ |
| 2019-01-02 | Gray Cameron | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.16 | 41.3K | 8,000 | — | ↗ |
| 2019-01-02 | DRISCOLL FREDERICK W | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.16 | 41.3K | 8,000 | — | ↗ |
| 2019-01-02 | DIGIANDOMENICO ANTHONY | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.16 | 41.3K | 8,000 | — | ↗ |
| 2018-12-31 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 18,521 | 4.64 | 85.9K | 89,602 | — | ↗ |
| 2018-12-28 | DIGIANDOMENICO ANTHONY | Director | P-Purchase | A | Common Stock | 7,000 | 4.62 | 32.3K | 57,000 | — | ↗ |
| 2018-12-27 | DIGIANDOMENICO ANTHONY | Director | P-Purchase | A | Common Stock | 20,000 | 4.77 | 95.4K | 50,000 | — | ↗ |
| 2018-12-26 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 19,647 | 4.29 | 84.3K | 71,081 | — | ↗ |
| 2018-12-24 | DIGIANDOMENICO ANTHONY | Director | P-Purchase | A | Common Stock | 10,000 | 4.81 | 48.1K | 30,000 | — | ↗ |
| 2018-12-21 | Suri Anish | Officer | P-Purchase | A | Common Stock | 2,000 | 4.37 | 8.7K | 2,000 | — | ↗ |
| 2018-12-21 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 17,200 | 4.53 | 77.9K | 51,434 | — | ↗ |
| 2018-12-21 | DIGIANDOMENICO ANTHONY | Director | P-Purchase | A | Common Stock | 10,000 | 4.49 | 44.9K | 20,000 | — | ↗ |
| 2018-12-20 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 9,438 | 4.74 | 44.7K | 34,234 | — | ↗ |
| 2018-12-19 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 400 | 5.00 | 2.0K | 24,796 | — | ↗ |
| 2018-12-18 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 3,664 | 5.20 | 19.1K | 24,396 | — | ↗ |
| 2018-12-17 | DIGIANDOMENICO ANTHONY | Director | P-Purchase | A | Common Stock | 10,000 | 5.48 | 54.8K | 10,000 | — | ↗ |
| 2018-12-13 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 10,000 | 5.06 | 50.6K | 20,732 | — | ↗ |
| 2018-12-12 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 3,189 | 5.07 | 16.2K | 10,732 | — | ↗ |
| 2018-12-11 | MARLETT CHRISTOPHER A | Director | P-Purchase | A | Common Stock | 7,543 | 4.86 | 36.7K | 7,543 | — | ↗ |
| 2018-08-29 | Millar Kerri-Ann | Officer | P-Purchase | A | Common Stock | 1,000 | 8.48 | 8.5K | 1,000 | — | ↗ |
| 2018-08-16 | PASSERI DANIEL R | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 8.09 | 48.5K | 47,600 | — | ↗ |
| 2018-08-14 | Suri Anish | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 8.26 | 165.2K | 20,000 | — | ↗ |
| 2018-08-01 | Mancilla Bethany | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 9.54 | 2.39M | 250,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-646.9K
Shares Outstanding
2.63M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Daniel R. Passeri Former Chief Executive Officer | 240.5K | — | — | 336.6K | — | 849.1K | 1.43M | 23.60% | ↗ |
| 2 | 2025 | Matteo Levisetti Former Chief Medical Officer | 470.8K | — | — | 187.0K | — | 561.6K | 1.22M | 15.33% | ↗ |
| 3 | 2025 | Usman Azam President and Chief Executive Officer | 143.1K | — | — | 1.04M | — | 249.00 | 1.19M | 87.91% | ↗ |
| 4 | 2025 | Lucinda Warren Chief Financial and Business Officer | 470.0K | — | — | 330.3K | — | 996.00 | 801.2K | 41.22% | ↗ |
| 5 | 2025 | Colin Sandercock SVP, General Counsel and Secretary | 448.6K | — | — | 149.6K | — | 996.00 | 599.2K | 24.96% | ↗ |
| 6 | 2024 | Daniel R. Passeri Chief Executive Officer | 492.9K | 186.7K | — | 711.2K | — | 3.2K | 1.39M | 51.02% | ↗ |
| 7 | 2024 | Daniel R. Passeri Former Chief Executive Officer | 492.9K | 186.7K | — | 711.2K | — | 3.2K | 1.39M | 51.02% | ↗ |
| 8 | 2024 | Matteo Levisetti Former Chief Medical Officer | 478.2K | 114.8K | — | 595.9K | — | 2.3K | 1.19M | 50.02% | ↗ |
| 9 | 2024 | Matteo Levisetti Chief Medical Officer | 478.2K | 114.8K | — | 595.9K | — | 2.3K | 1.19M | 50.02% | ↗ |
| 10 | 2024 | Anish Suri Former President and Chief Scientific Officer | 465.4K | — | — | 703.6K | — | 11.1K | 1.18M | 59.62% | ↗ |
| 11 | 2024 | Kerri-Ann Millar Chief Financial Officer | 463.0K | 111.1K | — | 467.5K | — | 3.2K | 1.04M | 44.75% | ↗ |
| 12 | 2023 | Daniel R. Passeri Chief Executive Officer | 604.8K | — | — | 2.41M | — | 3.2K | 3.02M | 79.84% | ↗ |
| 13 | 2023 | Anish Suri Former President and Chief Scientific Officer | 481.5K | — | — | 757.8K | — | 3.2K | 1.24M | 60.99% | ↗ |
| 14 | 2023 | Anish Suri President and Chief Scientific Officer | 481.5K | — | — | 757.8K | — | 3.2K | 1.24M | 60.99% | ↗ |
| 15 | 2023 | Kerri-Ann Millar Chief Financial Officer | 444.2K | — | — | 715.2K | — | 3.2K | 1.16M | 61.52% | ↗ |
| 16 | 2022 | Daniel R. Passeri Chief Executive Officer | 747.5K | 234.6K | — | 388.1K | — | 3.6K | 1.37M | 28.25% | ↗ |
| 17 | 2022 | Anish Suri President and Chief Scientific Officer | 489.8K | 148.6K | — | 525.7K | — | 3.6K | 1.17M | 45.02% | ↗ |
| 18 | 2022 | Kerri-Ann Millar Chief Financial Officer | 418.5K | 137.0K | — | 497.9K | — | 3.6K | 1.06M | 47.11% | ↗ |
| 19 | 2022 | Kerri Millar Chief Financial Officer | 418.5K | 137.0K | — | 497.9K | — | 3.6K | 1.06M | 47.11% | ↗ |
| 20 | 2021 | Daniel R. Passeri Chief Executive Officer | 531.0K | 239.1K | — | 1.05M | — | 4.7K | 1.82M | 57.45% | ↗ |
| 21 | 2021 | Anish Suri President and Chief Scientific Officer | 436.5K | 157.2K | — | 923.0K | — | 4.5K | 1.52M | 60.67% | ↗ |
| 22 | 2021 | Kerri-Ann Millar Chief Financial Officer | 374.2K | 118.1K | — | 861.5K | — | 4.2K | 1.36M | 63.44% | ↗ |
| 23 | 2021 | Kerri Millar Chief Financial Officer | 374.2K | 118.1K | — | 861.5K | — | 4.2K | 1.36M | 63.44% | ↗ |
| 24 | 2020 | Daniel R. Passeri Chief Executive Officer | 501.2K | 244.6K | 2.84M | 2.25M | — | 5.8K | 5.84M | 87.13% | ↗ |
| 25 | 2020 | Kerri-Ann Millar Chief Financial Officer | 292.5K | 108.1K | 397.4K | 1.39M | — | 4.1K | 2.19M | 81.56% | ↗ |
| 26 | 2020 | Anish Suri President and Chief Scientific Officer | 420.0K | 159.6K | 709.5K | 835.5K | — | 4.1K | 2.13M | 72.58% | ↗ |
| 27 | 2019 | Anish Suri President and Chief Scientific Officer | 366.3K | 376.5K | 753.0K | 3.06M | — | 4.1K | 4.56M | 83.62% | ↗ |
| 28 | 2019 | Daniel R. Passeri Chief Executive Officer | 395.0K | 187.6K | — | 610.2K | — | 5.8K | 1.20M | 50.91% | ↗ |
| 29 | 2019 | Colin Sandercock Senior Vice President, General Counsel and Secretary | 285.0K | 95.8K | — | 244.1K | — | 664.00 | 625.5K | 39.02% | ↗ |
| 30 | 2019 | Kerri-Ann Millar Chief Financial Officer | 215.0K | 82.8K | — | 146.5K | — | 4.1K | 448.3K | 32.67% | ↗ |
| 31 | 2018 | Anish Suri President and Chief Scientific Officer | 207.9K | 106.5K | — | 2.85M | — | 53.1K | 3.22M | 88.62% | ↗ |
| 32 | 2018 | Anish Suri Chief Scientific Officer | 207.9K | 106.5K | — | 2.85M | — | 53.1K | 3.22M | 88.62% | ↗ |
| 33 | 2018 | Daniel R. Passeri Chief Executive Officer | 345.0K | 103.5K | — | 381.2K | — | 4.2K | 833.9K | 45.71% | ↗ |
| 34 | 2018 | Daniel R. Passeri Chief Executive Officer, President | 345.0K | 103.5K | — | 381.2K | — | 4.2K | 833.9K | 45.71% | ↗ |
| 35 | 2018 | Colin Sandercock Senior Vice President, General Counsel and Secretary | 275.0K | 55.0K | — | — | — | 220.00 | 330.2K | 0.00% | ↗ |
| 36 | 2017 | Colin G. Sandercock Senior Vice President & General Counsel | 22.9K | 6.2K | — | 1.21M | — | — | 1.24M | 97.64% | ↗ |
| 37 | 2017 | Colin Sandercock Senior Vice President, General Counsel and Secretary | 22.9K | 6.2K | — | 1.21M | — | — | 1.24M | 97.64% | ↗ |
| 38 | 2017 | Daniel R. Passeri Chief Executive Officer, President | 325.0K | 81.2K | — | — | — | 4.2K | 406.2K | 0.00% | ↗ |
| 39 | 2017 | Ronald D. Seidel Executive Vice President, Head of Research & Development | 250.0K | 62.5K | — | — | — | 4.2K | 312.5K | 0.00% | ↗ |
| 40 | 2017 | Rodolfo J. Chaparro Executive Vice President, Head of Immunology | 250.0K | 62.5K | — | — | — | 4.2K | 312.5K | 0.00% | ↗ |
| 41 | 2016 | Daniel R. Passeri Chief Executive Officer, President | 112.0K | 57.5K | — | 2.29M | — | 1.2K | 2.46M | 93.11% | ↗ |
| 42 | 2016 | Ronald D. Seidel Executive Vice President, Head of Research & Development | 203.3K | 50.0K | — | 504.1K | — | 3.6K | 757.5K | 66.56% | ↗ |
| 43 | 2016 | Rodolfo J. Chaparro Executive Vice President, Head of Immunology | 203.3K | 50.0K | — | 504.1K | — | 3.6K | 757.5K | 66.56% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lucinda Warren | Principal Fin & Accounting Off. and Chief Financial & Business Officer | 470.9K | female |
| Colin G. Sandercock | Senior Vice President, General Counsel & Secretary | 449.6K | male |
| Usman Azam | President, CEO & Director | 434.2K | — |
| Shao-Lee Lin | President, CEO & Director | 434.2K | — |
| Ronald D. Seidel | Co-Founder | 316.6K | — |
| Rodolfo J. Chaparro | Co-Founder | 316.6K | — |
| Daniel G. Baker | Interim Chief Development Officer | — | — |
| Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CUE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
